Oncg100- A Phase 2, Multicenter Open-Label, Non-Randomized Study Of Bavituximab Plus Pembrolizumab In Patients With Advanced Gastric Or Gastroesophageal Cancer Who Have Progressed On Or After At Least One Prior Standard Therapy
Posted Date: Feb 24, 2020
- Investigator: Olugbenga Olowokure
- Specialties: Cancer, Oncology
- Type of Study: Drug
The primary goal of this study is to assess the safety and tolerability, and antitumor activity of bavituximab in combination with pembrolizumab in patients with advanced gastric/GEJ cancer.
Criteria:
To Be Eligible: Must Have Unresectable Metastatic Or Locally Advanced Gastric Or Gej Adenocarcinoma, At Least One Measurable Lesion, Ecog 0-1, No Surgery Or Rt With 4 Wks, Other Malignancy Within 3 Years, Hx Of Or Active Illness That May Impact Study
Keywords:
Gastroesophageal Cancer, Gastrointestinal, Gi
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com